Protalix Biotherapeutics (De) (PLX) closed at $3.06 on November 19, 2026, up 1.3% from the previous close, on volume of 1,554,365 shares (30-day average 977,323).
Data as of November 19, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 19, 2026 | Call Spread | 20-Nov-260.5 : 1 C | 318 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
PRNewswire (Tue, 10-Nov 6:45 AM ET)
PRNewswire (Mon, 9-Nov 6:45 AM ET)
PRNewswire (Tue, 3-Nov 6:50 AM ET)
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference
PRNewswire (Mon, 26-Oct 6:50 AM ET)
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
PRNewswire (Tue, 8-Sep 6:45 AM ET)
Protalix Posts Record Revenue Growth and Achieves Profitability, Backed by Strong Pipeline Progress
Market Chameleon (Wed, 12-Aug 7:55 AM ET)
PLX Profit Swing Driven by $25M Milestone and Record Net Income in Q1 2026
Market Chameleon (Wed, 13-May 7:23 AM ET)
Market Chameleon (Mon, 2-Feb 6:09 AM ET)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.
As of November 20, 2026, PLX stock price declined to $3.00 with 416,474 million shares trading.
PLX has a beta of 1.61, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.12 to the broad based SPY ETF.
PLX has a market cap of $252.96 million. This is considered a Small Cap stock.
Last quarter Protalix Biotherapeutics (De) reported $22 million in Revenue and $.05 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.07.
In the last 3 years, PLX traded as high as $3.19 and as low as $.82.
The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, IWC, DFAS.
PLX has outperformed the market in the last year with a price return of +69.5% while the SPY ETF gained +7.3%. PLX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +27.7% and +19.5%, respectively, while the SPY returned -8.3% and -4.1%, respectively.
PLX support price is $2.96 and resistance is $3.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.